

Virtual Radiologic Corp Announces Fourth Quarter and Full Year 2009 Financial Results

Reports 2009 Revenue up 13 Percent to \$120.7 Million and Adjusted EBITDA up 34 Percent to \$27.6 Million; Provides 2010 Guidance

MINNEAPOLIS, Minn., January 25, 2010 -- Virtual Radiologic Corp. (NASDAQ: VRAD), a leading provider of virtual radiology services and technology solutions, today reported financial results for its fourth quarter and full year ended December 31, 2009.

Full Year Financial Highlights

- Read volume up 21% to 2.7 million
- Revenue up 13% to \$120.7 million
- Adjusted EBITDA⁽¹⁾ up 34% to \$27.6 million and 23% of revenue
- Adjusted net income⁽²⁾ up 31% to \$12.7 million; adjusted diluted earnings per share⁽³⁾ (EPS) up 37% to \$0.78
- GAAP net income of \$7.9 million; GAAP diluted EPS of \$0.48
- Cash of \$50.2 million, up from cash and short-term investments of \$29.3 million at December 31, 2008; the Company has no debt

Fourth Quarter Financial Highlights

- Read volume up 16% to 687,000
- Revenue up 6% to \$29.9 million
- Adjusted EBITDA⁽¹⁾ up 16% to \$5.8 million and 19% of revenue
 Adjusted net income⁽²⁾ up 18% to \$2.4 million; adjusted diluted earnings per share⁽³⁾ (EPS) up 25% to \$0.15
- GAAP net income of \$1.1 million; GAAP diluted EPS of \$0.07

Additional Fourth Quarter Highlights

- Finals volume grew 47%, representing 32% of total volume
- Ranked #1 in Teleradiology Services by KLAS for second consecutive year
- Released vRad Enterprise Connect 2.1, providing radiology practices with added productivity and growth tools
- Named to Deloitte's 2009 Technology Fast 500™
- Completed deployment of proprietary vRad PACS to all of its 143 affiliated radiologists

"We are pleased with our full year financial performance despite the challenging economic environment that existed throughout 2009," said Rob Kill, Virtual Radiologic's president and chief executive officer. "We believe we have positioned Virtual Radiologic to continue as the innovative growth leader in the virtual radiology arena."

Fourth Quarter and Full Year Results

Total revenue increased 6% to \$29.9 million and 13% to \$120.7 million for the three and twelve months ended December 31, 2009, compared to \$28.3 million and \$106.6 million for the three and twelve months ended December 31, 2008. The increase in revenue over the fourth quarter and full year of 2008 resulted primarily from a 14% year-over-year increase in the number of hospitals and medical facilities served to 1,173 as of December 31, 2009, representing approximately 19% of all hospitals in the United States.

Adjusted EBITDA increased 16% to \$5.8 million and 34% to \$27.6 million for the three and twelve months ended December 31, 2009, compared to \$5.0 million and \$20.5 million for the three and twelve months ended December 31, 2008. Adjusted EBITDA was 19% and 23% of revenue for the three and twelve months ended December 31, 2009 compared to 18% and 19% for the prior year periods.

Adjusted net income increased 18% to \$2.4 million and 31% to \$12.7 million for the three and twelve months ended December 31, 2009, compared to \$2.0 million and \$9.7 million for the three and twelve months ended December 31, 2008. This resulted in an adjusted diluted EPS of \$0.15 and \$0.78 for the three and twelve months ended December 31, 2009, compared to \$0.12 and \$0.57 for the three and twelve months ended December 31, 2008.

GAAP net income was \$1.1 million and \$7.9 million for the three and twelve months ended December 31, 2009, compared to \$890,000 and \$8.5 million for the three and twelve months ended December 31, 2008, resulting in diluted earnings per share of \$0.07 and \$0.48 for the three and twelve months ended December 31, 2009, compared to \$0.05 and \$0.50 for the three and twelve months ended December 31, 2008, respectively.

2010 Guidance

The Company is providing the following guidance for the full year of 2010:

- Revenue ranging from \$127.0 million to \$131.0 million
- Adjusted EBITDA ranging from \$28.0 million to \$30.0 million
- Adjusted net income ranging from \$12.6 million to \$13.8 million
- Adjusted diluted earnings per share ranging from \$0.75 to \$0.82

Conference Call Information

The Company will be hosting a conference call January 25, 2010 at 4:30 p.m. Eastern Time to discuss these results and provide a general business update. Participants can access the call by dialing (800) 561-2693 (within the United States and Canada), or (617) 614-3523 (outside the United States and Canada), using passcode 78354286. A live webcast of the conference call will be available on the Company's corporate web site at http://ir.virtualrad.com under "Calendar of Events." A replay of the call will be available from 7:30 p.m. Eastern Time on Monday, January 25, 2010, through midnight on Monday, February 1, 2010. Access the replay by dialing (888) 286-8010 or (617) 801-6888, using passcode 62331925.

About Virtual Radiologic

Virtual Radiologic Corporation (vRad) is a national radiology practice working in partnership with radiologists and hospitals to optimize radiology's pivotal role in the delivery of patient care. Enabled by next-generation technology, vRad's collaborative partnerships enhance productivity and deliver demonstrated quality outcomes that help lower the overall cost of care. vRad's 143 affiliated radiologists serve 1,170 facilities (nearly 20% of U.S. hospitals), reading more than 2.6 million interpretations annually with unparalleled subspecialist expertise and expedited time to diagnosis. Continually recognized for high-quality reports and industry-leading service, vRad is ranked #1 in the teleradiology services category by independent healthcare research firm KLAS and has received the Joint Commission Gold Seal of Approval each year since 2004. For more information, visit www.vrad.com.

Safe Harbor for Forward-Looking and Cautionary Statements

Certain statements in this press release are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, including, in particular, statements about plans, objectives, strategies and prospects regarding, among other things, vRad's business and results of operations. These statements can be identified by the use of words such as "will," "believe," "expect," and "anticipate" and similar terms or expressions of future expectation. These statements involve a number of risks, uncertainties and other factors that could cause actual results, performance or achievements of vRad to be materially different from any future results, performance or achievements expressed or implied by these forward-looking statements. For examples of such risks and uncertainties, please see vRad's Annual Report on Form 10-K, as well as other filings with the Securities and Exchange Commission. vRad undertakes no duty to update these forward-looking statements due to new information or as a result of future events.

Notes Regarding the Use of Non-GAAP Financial Measures

vRad records its results of operations in accordance with accounting principles generally accepted in the United States of America ("GAAP"). In addition, vRad is providing certain supplemental non-GAAP information which the Company believes to be an important indicator of its financial performance. vRad uses the following non-GAAP financial measures:

- Adjusted EBITDA net income excluding the net effects of interest, income taxes, depreciation and amortization, non-cash stock-based compensation expense and medical malpractice loss reserves (other than specific case reserves);
- Adjusted net income net income excluding the effects of non-cash stock-based compensation, net of tax, and medical malpractice loss reserves (other than specific case reserves), net of tax; and

• Adjusted diluted earnings per share – adjusted net income divided by weighted average diluted shares outstanding.

vRad presents these non-GAAP financial measures because it believes that they are a useful indicator of its performance and on-going operations. The Company believes that these non-GAAP financial measures are useful to investors in part because such measures are frequently used by securities analysts to measure a company's operating performance without regard to certain items, such as income tax expense, net interest income and depreciation and amortization, which can vary substantially from company to company. vRad's management also uses these non-GAAP financial measures in order to review and assess its operating performance and its management team in connection with certain incentive programs and the preparation of its financial projections.

Adjusted EBITDA, adjusted net income and adjusted diluted earnings per share are not measurements of the Company's financial performance under GAAP and may not be comparable to the calculation of similarly titled measures reported by other companies. These measures should not be considered as an alternative to net income, earnings per share or any other performance measures derived in accordance with GAAP.

Contact

Mollie O'Brien Director, Investor and Public Relations mollie.obrien@vrad.com (952) 595-1196

SOURCE: Virtual Radiologic Corporation

http://www.vrad.com

⁽¹⁾ Adjusted EBITDA consists of net income excluding the net effects of interest, income taxes, depreciation and amortization, non-cash stock-based compensation expense and medical malpractice loss reserves (other than specific case reserves). See "Notes Regarding the Use of Non-GAAP Financial Measures" and "Supplemental Information and Non-GAAP Reconciliations" for more information related to adjusted EBITDA.

⁽²⁾ Adjusted net income consists of net income excluding the effects of non-cash stock-based compensation, net of tax, and medical malpractice loss reserves (other than specific case reserves), net of tax. See "Notes Regarding the Use of Non-GAAP Financial Measures" and "Supplemental Information and Non-GAAP Reconciliations" for more information related to adjusted net income.

⁽³⁾ Adjusted diluted earnings per share consists of adjusted net income divided by weighted average diluted shares outstanding. See "Notes Regarding the Use of Non-GAAP Financial Measures" and "Supplemental Information and Non-GAAP Reconciliations" for more information related to adjusted diluted earnings per share.

CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited)

(in thousands, except per share data)

	Three Months En	ded Dec	ember 31,		Year Ended I	Decembe	er 31,
_	2009		2008		2009		2008
Revenue <u>s</u>	29,945	\$	28,301	\$	120,736	\$	106,567
Operating costs and expenses							
Professional services	15,280		14,187		58,735		49,363
Sales, general and administrative	11,046		11,050		42,317		38,717
Depreciation and amortization	1,871		1,343		6,863		4,700
Total operating costs and expenses	28,197		26,580		107,915		92,780
Operating income	1,748		1,721		12,821		13,787
Other income (expense)							
Interest income	63		149		220		599
Interest expense					(5)		
Total other income	63		149		215		599
Income before income tax expense	1,811		1,870		13,036		14,386
Income tax expense	726		976		5,143		5,918
Net income	1,085		894		7,893		8,468
Non-controlling interest expense	<u>-</u>		4				14_
Net income attributable to Virtual Radiologic	1,085	\$	890	\$	7,893	\$	8,454
Earnings per common share							
Basic	0.07	\$	0.06	\$	0.50	\$	0.51
Diluted	0.07	\$	0.05	\$	0.48	\$	0.50
Weighted average common shares outstanding	•	•		•		•	
Basic	15,907		15,938		15,872		16,500
Diluted	16,332		16,256		16,283		16,976

	ENTAL NON-GAAP I (Unaudite thousands, except	ed)						
_	Three Months En	ded Dec	ember 31,		Year Ended	Decembe	r 31,	
	2009 2008 2009				2009	2008		
Adjusted EBITDA ⁽¹⁾	\$ 5,799	\$	4,983	\$	27,560	\$	20,549	
Adjusted net income ⁽¹⁾	\$ 2,391	\$	2,023	\$	12,662	\$	9,681	
Adjusted diluted earnings per share ⁽¹⁾	\$ 0.15	\$	0.12	\$	0.78	\$	0.57	

SUPPLEMENTAL INFORMATION AND NON-GAAP RECONCILIATIONS (Unaudited)

(in thousands, except per share data)

The following table reconciles the GAAP financial measure of Net income to the non-GAAP supplemental financial measure of Adjusted EBITDA which excludes the effects of interest, income taxes, depreciation and amortization, non-cash stock-based compensation expense, and medical malpractice loss reserves (other than specific case reserves). See "Notes Regarding the Use of Non-GAAP Financial Measures" for more information related to the non-GAAP financial measures presented in this table.

	Three Mon Decemb			Ended iber 31,
<u> </u>	2009	2008	2009	2008
Reconciliation of Net income to Adjusted EBITDA:				
Net income <u>\$</u>	1,085	\$ 894	\$ 7,893	\$ 8,468
Income tax expense	726	976	5,143	5,918
Interest income, net	(63)	(149)	(215)	(599)
Depreciation and amortization	1,871	1,343	6,863	4,700
EBITDA	3,619	3,064	19,684	18,487
Physician non-cash stock-based compensation	134	499	787	(479)
Employee non-cash stock-based compensation	585	423	2,420	1,544
Medical malpractice loss reserves ⁽¹⁾	1,461	997	4,669	997
Adjusted EBITDA\$	5,799	\$ 4,983	\$ 27,560	\$ 20,549

The following table reconciles the GAAP financial measures of Net income and Diluted earnings per share to the non-GAAP supplemental financial measures of Adjusted net income and Adjusted diluted earnings per share which exclude the effects of non-cash stock-based compensation expense, net of tax, and medical malpractice loss reserves (other than specific case reserves), net of tax. See "Notes Regarding the Use of Non-GAAP Financial Measures" for more information related to the non-GAAP financial measures presented in this table.

		Three Months Ended December 31,					r Ended mber 3:	
		2009		2008		2009		2008
Reconciliation of Net income to Adjusted net income:								
Net income	\$	1,085	\$	894	\$	7,893	\$	8,468
Physician non-cash stock-based compensation, net of tax		80		293		477		(282
Employee non-cash stock-based compensation, net of tax		350		249		1,465		908
Medical malpractice loss reserves, net of tax ⁽¹⁾	<u> </u>	876		587		2,827		587
Adjusted net income	\$	2,391	\$	2,023	\$	12,662	\$	9,681
Reconciliation of Diluted earning per share to Adjusted diluted earnings per	share:							
Reconciliation of Diluted earning per share to Adjusted diluted earnings per		0.07	\$	0.05	\$	0.48	<u>\$</u>	0.50
	<u>\$</u>	0.07	_\$	0.05	_\$_	0.48	_\$	
Diluted earnings per share Physician non-cash stock-based compensation, net of tax Employee non-cash stock-based compensation, net of tax	<u>\$</u>		_\$_		_\$_		_\$	0.50 (0.02 0.05
Diluted earnings per sharePhysician non-cash stock-based compensation, net of tax	<u>\$</u>	0.01	\$	0.02	<u>\$</u>	0.03	<u>\$</u>	(0.02
Diluted earnings per share Physician non-cash stock-based compensation, net of tax Employee non-cash stock-based compensation, net of tax	<u>\$</u>	0.01 0.02	\$	0.02 0.01	\$	0.03 0.09	\$	(0.02 0.05
Diluted earnings per share Physician non-cash stock-based compensation, net of tax Employee non-cash stock-based compensation, net of tax Medical malpractice loss reserves, net of tax ⁽¹⁾	\$ <u>\$</u>	0.01 0.02 0.05	\$	0.02 0.01 0.04	\$	0.03 0.09 0.18	\$	(0.02 0.05 0.04
Diluted earnings per share	\$ <u>\$</u>	0.01 0.02 0.05 0.15	\$	0.02 0.01 0.04 0.12	\$	0.03 0.09 0.18 0.78	\$	(0.02 0.05 0.04 0.57

SUPPLEMENTAL INFORMATION AND NON-GAAP RECONCILIATIONS - CONTINUED (Unaudited)

(in millions, except per share data)

The following tables reconcile the non-GAAP financial measures provided in the Company's fiscal year 2010 guidance to their closest comparable GAAP financial measure. See "Notes Regarding the Use of Non-GAAP Financial Measures" for more information related to the non-GAAP financial measures presented in this table.

		Year Ended December 31, 2010			
Net income		6.9		\$	8.1
Income tax expense		4.6			5.4
Interest income, net		(0.2)			(0.2)
Depreciation and amortization		7.3	_		7.3
EBITDA	···· <u> </u>	18.6	_		20.6
Physician non-cash stock-based compensation		1.2	-		1.2
Employee non-cash stock-based compensation		2.6	-		2.6
Medical malpractice loss reserves		5.6	_		5.6
Adjusted EBITDA	<u>\$</u>	28.0	= -:	\$	30.0
Net income			_	\$	8.1
Physician non-cash stock-based compensation, net of tax		0.7	-		0.7
Employee non-cash stock-based compensation, net of tax		1.6	-		1.6
Medical malpractice loss reserves, net of tax		3.4	_		3.4
Adjusted net income	<u>\$</u>	12.6		\$	13.8
Diluted earnings per share	\$	0.41	_	\$	0.48
Physician non-cash stock-based compensation, net of tax		0.04			0.04
Employee non-cash stock-based compensation, net of tax		0.10	-		0.10
Medical malpractice loss reserves, net of tax		0.20	-		0.20
Adjusted diluted earnings per share	\$	0.75	- -	\$	0.82
Diluted weighted average shares outstanding ⁽¹⁾					16.7
$^{(1)}$ Diluted weighted average shares outstanding for the full year 2010 are calculated using the accordance with GAAP based on forecast assumptions made by the Company.	ne trea	sury sto	ıck	me	thod in

CONDENSED CONSOLIDATED BALANCE SHEETS AND SELECTED OPERATING DATA (Unaudited)

	As of December 31, 2009		Dece	As of mber 31, 2008	
	(in thousand			nds)	
Cash and cash equivalents	\$	50,163	\$	19,180	
Short-term investments		-		10,136	
Accounts receivable, net		17,384		17,383	
Other current assets		4,258		4,826	
Other assets		22,396		19,476	
Total assets	. \$	94,201	\$	71,001	
Current liabilities	. \$	14,848	\$	11,087	
Other liabilities		10,522		3,397	
Total liabilities		25,370		14,484	
Total stockholders' equity		68,831		56,517	
Total liabilities and stockholders' equity	. \$	94,201	\$	71,001	

	As of Decem	ıber 31,
	2009	2008
Affiliated radiologists providing services	143	134
Customers	655	621
Hospitals and other medical facilities served	1,173	1,026

	Three Month Decembe		Year End Decembe	
	2009	2008	2009	2008
Total reads	687,298	591,091	2,668,043	2,200,365
Percentage growth over prior year period	16%	30%	21%	30%
Same site volume growth ⁽¹⁾	7%	2%	5%	6%
Percentage of read revenue from final reads	32%	27%	28%	24%

⁽¹⁾ Same-site volume growth is calculated as the percentage increase in the number of reads over the comparable prior year period generated by a facility that has been under contract for at least three months at the beginning of the measurement period and remains a customer throughout that period.